Delphine Planas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3597485/publications.pdf

Version: 2024-02-01

42 papers	6,570 citations	279798 23 h-index	276875 41 g-index
64 all docs	64 docs citations	64 times ranked	10557 citing authors

#	Article	IF	Citations
1	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature, 2022, 602, 671-675.	27.8	1,202
2	Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Annals of the Rheumatic Diseases, 2022, 81, 720-728.	0.9	39
3	Flow Cytometry Sorting of Memory CCR6+CD4+ T-Cells for HIV Reservoir Quantification. Methods in Molecular Biology, 2022, 2407, 81-89.	0.9	0
4	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrology Dialysis Transplantation, 2022, 37, 1357-1365.	0.7	17
5	Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. American Journal of Transplantation, 2022, 22, 2099-2103.	4.7	14
6	Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. Blood, 2022, 139, 942-946.	1.4	24
7	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. Kidney International, 2022, 101, 1073-1076.	5.2	44
8	Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. Frontiers in Immunology, 2022, 13, 790212.	4.8	3
9	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. EBioMedicine, 2022, 77, 103934.	6.1	10
10	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nature Medicine, 2022, 28, 1297-1302.	30.7	235
11	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120976119.	7.1	27
12	Potent human broadly SARS-CoV-2â€“neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	8.5	34
13	Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses, 2022, 14, 1491.	3.3	13
14	Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells. Journal of Virology, 2022, 96, .	3.4	10
15	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nature Communications, 2021, 12, 844.	12.8	146
16	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine, 2021, 65, 103270.	6.1	46
17	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Medicine, 2021, 27, 917-924.	30.7	617
18	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1337-e1344.	5.8	35

#	Article	IF	Citations
19	Diurnal Variation of Plasma Extracellular Vesicle Is Disrupted in People Living with HIV. Pathogens, 2021, 10, 518.	2.8	5
20	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 2021, 596, 276-280.	27.8	1,803
21	Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual. Open Forum Infectious Diseases, 2021, 8, ofab369.	0.9	2
22	Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. Journal of Infectious Diseases, 2021, 224, 1489-1499.	4.0	32
23	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nature Communications, 2021, 12, 5215.	12.8	22
24	Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine, 2021, 71, 103561.	6.1	172
25	SARSâ€CoVâ€2 Alpha, Beta, and Delta variants display enhanced Spikeâ€mediated syncytia formation. EMBO Journal, 2021, 40, e108944.	7.8	139
26	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. EBioMedicine, 2021, 73, 103637.	6.1	19
27	Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	17
28	Syncytia formation by SARSâ€CoVâ€2â€infected cells. EMBO Journal, 2020, 39, e106267.	7.8	361
29	Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota. Open Forum Infectious Diseases, 2020, 7, ofaa338.	0.9	33
30	A comparison of four serological assays for detecting antiâ€“SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine, 2020, 12, .	12.4	228
31	Daily variations of gut microbial translocation markers in ART-treated HIV-infected people. AIDS Research and Therapy, 2020, 17, 15.	1.7	14
32	Improving HIV Outgrowth by Optimizing Cell-Culture Conditions and Supplementing With all-trans Retinoic Acid. Frontiers in Microbiology, 2020, 11, 902.	3.5	15
33	Pharmacological Inhibition of PPAR_y Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and <i>de novo</i> Infection. Pathogens and Immunity, 2020, 5, 177.	3.1	12
34	New Th17-specific therapeutic strategies for HIV remission. Current Opinion in HIV and AIDS, 2019, 14, 85-92.	3.8	30
35	Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. BMJ Open, 2019, 9, e028444.	1.9	39
36	HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy. Aids, 2019, 33, 1293-1306.	2.2	28

#	Article	IF	Citations
37	HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. Aids, 2017, 31, 35-48.	2.2	122
38	HIV-1 selectively targets gut-homing CCR6+CD4+ T cells via mTOR-dependent mechanisms. JCI Insight, 2017, 2, .	5.0	75
39	Digoxin reveals a functional connection between HIV-1 integration preference and T-cell activation. PLoS Pathogens, 2017, 13, e1006460.	4.7	21
40	Identification of novel HIV-1 dependency factors in primary CCR4+CCR6+Th17 cells via a genome-wide transcriptional approach. Retrovirology, 2015, 12, 102.	2.0	54
41	Persistence of Sera Neutralizing Activity Six Month after Hospitalization for COVID-19. SSRN Electronic Journal, 0, , .	0.4	0
42	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature, 0, , .	27.8	88